ILDR2 Is a Novel B7-like Protein That Negatively Regulates T Cell Responses

J Immunol. 2018 Mar 15;200(6):2025-2037. doi: 10.4049/jimmunol.1700325. Epub 2018 Feb 5.

Abstract

The B7-like protein family members play critical immunomodulatory roles and constitute attractive targets for the development of novel therapies for human diseases. We identified Ig-like domain-containing receptor (ILDR)2 as a novel B7-like protein with robust T cell inhibitory activity, expressed in immune cells and in immune-privileged and inflamed tissues. A fusion protein, consisting of ILDR2 extracellular domain with an Fc fragment, that binds to a putative counterpart on activated T cells showed a beneficial effect in the collagen-induced arthritis model and abrogated the production of proinflammatory cytokines and chemokines in autologous synovial-like cocultures of macrophages and cytokine-stimulated T cells. Collectively, these findings point to ILDR2 as a novel negative regulator for T cells, with potential roles in the development of immune-related diseases, including autoimmunity and cancer.

MeSH terms

  • Animals
  • B7 Antigens / immunology*
  • Cells, Cultured
  • Cytokines / immunology
  • Humans
  • Immunoglobulin Domains / immunology
  • Immunoglobulin Fc Fragments / immunology
  • Lymphocyte Activation / immunology
  • Macrophages / immunology
  • Male
  • Membrane Proteins / immunology*
  • Mice
  • Mice, Inbred BALB C
  • T-Lymphocytes / immunology*

Substances

  • B7 Antigens
  • Cytokines
  • ILDR2 protein, mouse
  • Immunoglobulin Fc Fragments
  • Membrane Proteins